EVFM vs. APVO, HOTH, XCUR, CLVR, TRVN, HEPA, EVOK, GNPX, CPHI, and GTBP
Should you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Aptevo Therapeutics (APVO), Hoth Therapeutics (HOTH), Exicure (XCUR), Clever Leaves (CLVR), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), Evoke Pharma (EVOK), Genprex (GNPX), China Pharma (CPHI), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
Evofem Biosciences received 64 more outperform votes than Aptevo Therapeutics when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 52.24% of users gave Aptevo Therapeutics an outperform vote.
In the previous week, Aptevo Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 3 mentions for Aptevo Therapeutics and 2 mentions for Evofem Biosciences. Evofem Biosciences' average media sentiment score of 0.14 beat Aptevo Therapeutics' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.
Aptevo Therapeutics has a beta of 5.2, indicating that its share price is 420% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.74, indicating that its share price is 174% less volatile than the S&P 500.
Evofem Biosciences has higher revenue and earnings than Aptevo Therapeutics.
8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 0.2% of Evofem Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Evofem Biosciences has a net margin of 315.54% compared to Evofem Biosciences' net margin of 0.00%. Aptevo Therapeutics' return on equity of -81.10% beat Evofem Biosciences' return on equity.
Summary
Aptevo Therapeutics beats Evofem Biosciences on 8 of the 15 factors compared between the two stocks.
Get Evofem Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evofem Biosciences Competitors List
Related Companies and Tools
